Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer-Reference-Cited by-同舟云学术

Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer

Published:2020-01-01 Issue:1 Volume:9 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Liang Tingting¹,Tong Weihua²,Ma Siyang³,Chang Pengyu³^ORCID

Affiliation:

1. Oncology Department, The First Hospital of Jilin University, Changchun, P.R. China

2. Department of Gastrointestinal and Colorectal Surgery, The First Hospital of Jilin University, Changchun, P.R. China

3. Department of Radiation Oncology & Therapy, Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, P.R. China

Funder

National Natural Science Foundation of China

Scientific and Technological Developing Scheme of Jilin Province

Scientific Research Planning Project of the 13th Five-year Plan of Jilin Provincial Department of Education

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2020.1773205

Reference82 articles.

1. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

2. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

3. Results and challenges of immune checkpoint inhibitors in colorectal cancer

4. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

5. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer;Science Advances;2022-12-16

2. Trial watch: Dendritic cell (DC)-based immunotherapy for cancer;OncoImmunology;2022-07-04

3. KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas;Cancers;2021-05-18